Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca, Takeda strike Parkinson’s drug deal

AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.

Read More »

AstraZeneca taps AI for drug discovery deal

AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.

Read More »

CSL Behring Scoops U.S. Biotech Calimmune

CSL Ltd. bought Tucson, Ariz.-based Calimmune for $91 million upfront and up to $325 million in performance-based milestones.

Read More »

Takeda, BioSurfaces Announce Research Program

Takeda and BioSurfaces announced a deal to initiate a research program designed to develop innovative medical devices to treat patients with GI diseases.

Read More »

Ablynx signs Sanofi deal potentially worth up to $2.8 billion

French drugmaker Sanofi boosted its early-stage pipeline in immunology by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Read More »

Novartis Boss Updates Q2 2017 Financials, Reaffirms M&A Strategy

Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.

Read More »

GlaxoSmithKline Ends R&D Pact with OncoMed

OncoMed announced GlaxoSmithKline was terminating its nearly 10-year-old R&D agreement. OncoMed’s shares fell about 2 percent on the news.

Read More »

Bay Area’s Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug

Tokyo-based Daiichi Sankyo Company announced that it was ending its development deal of CHS-0214 with Coherus Biosciences.

Read More »

GSK signs AI drug discovery deal

The world’s leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines.

Read More »

Bay Area Biotech, J&J Ink IBS Deal

J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom